Genmab (0MGB)

2,653.00
+14.00(+0.53%)
  • Volume:
    1,318
  • Bid/Ask:
    2,601.00/2,709.00
  • Day's Range:
    2,653.00 - 2,653.00

0MGB Overview

Prev. Close
2,641
Day's Range
2,653-2,653
Revenue
9.37B
Open
2,653.5
52 wk Range
1,864-3,325
EPS
86.43
Volume
1,318
Market Cap
173.67B
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
19,615
P/E Ratio
30.54
Beta
0.736
1-Year Change
22.78%
Shares Outstanding
65,361,690
Next Earnings Date
22 Feb 2023
What is your sentiment on Genmab?
or
Vote to see community's results!

Genmab News

Genmab Company Profile

Genmab Company Profile

Employees
1445
Market
Denmark

Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyNeutralStrong SellBuy
Technical IndicatorsStrong BuyStrong BuyBuyStrong SellStrong Buy
SummaryStrong BuyStrong BuyNeutralStrong SellStrong Buy